Mazdutide

Mazdutide (IBI362) is a dual glucagon and GLP-1 receptor agonist by Innovent Biologics/Eli Lilly, based on oxyntomodulin scaffolding and approved by China's NMPA for chronic weight management. It combines GLP-1 effects on insulin secretion and appetite with glucagon's metabolic and hepatic fat oxidation benefits, creating enhanced energy expenditure and lipid metabolism. Mazdutide 9mg is the only dual agonist achieving over 20% weight loss in obese adults without type 2 diabetes with just 2-step dose titration, and in head-to-head Phase 3 comparison demonstrated superiority to semaglutide across both glucose control and weight loss metrics.

10mg